Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP173 | DOI: 10.1530/endoabs.81.EP173

ECE2022 Eposter Presentations Calcium and Bone (114 abstracts)

Palovarotene for the treatment of fibrodysplasia ossificans progressiva: methodology of the phase III open-label PIVOINE rollover trial

Alexander Artyomenko 1 , Aude Houchard 2 & Azzeddine Zemam 2


1Ipsen, Slough, UK; 2Ipsen, Boulogne-Billancourt, France.


Objectives: Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by heterotopic ossification (HO) and progressive restriction of mobility. To date, no approved disease-modifying treatments for FOP exist, but interim phase III trial (NCT03312634) results suggest marked efficacy for palovarotene (PVO).1 Here, we describe methodology of the PIVOINE trial (NCT05027802) designed to allow treatment continuity and further evaluation of PVO safety and efficacy.

Methods: Patients will receive 5 mg PVO daily, or the parent study completion dose, for a maximum of 3 years; during flare-ups, patients will receive 20 mg daily for 4 weeks, then 10 mg daily for 8 weeks. Enrollment criteria: completion of a parent study (end of study/treatment visit of NCT03312634 or NCT02279095/NCT02979769), ≥14 years old, full skeletal maturity if aged <18 years or deemed to be final adult height. PIVOINE aims to enroll 61 patients; recruitment has not begun. Outcomes are presented in Table.

Summary: Results from PIVOINE, estimated to end in November 2024, will allow further evaluation of PVO in FOP.

References: 1. Pignolo R et al. ASBMR 2020;35(Suppl 1):16–17.

Funding: Sponsored by Ipsen.

Table: Trial outcomes
Primary
Incidence of treatment-emergent adverse eventsa
Secondaryb
Cumulative Analogue Joint Involvement Scale (CAJIS) total scorec
Use of aids, assistive devices and adaptationsc
FOP-Physical Function Questionnaire percentage of worst score (total score; upper extremities/mobility sub-scores)c
Frequency of healthcare utilization
Observed/percentage predicted:c Forced vital capacity (FVC) Forced expiratory volume in 1 second (FEV1) Diffusion capacity of the lung for carbon monoxide (DLCO) Absolute/percentage predicted:c FEV1/FVC ratio
Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale physical and mental function scoresc
Number of investigator-reported flare-ups, outcomes and durationc
Percentage of patients with new bone growth
aCollected continuously over trial period; bCollected every 6 months over trial period; cRaw values and change from inclusion visit.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.